Assessing heart damage in young cancer survivors
Official title: CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
Run by University of California, San Diego · NCT04262830 · Data updated 2026-11-12
This study is trying to find out if heart damage can be detected early in young cancer survivors who received certain chemotherapy treatments, to help prevent future heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 13 Years to 39 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University of California, San Diego Academic / other |
| Drugs / interventions | doxorubicin |
| Locations | 1 site (San Diego, California) |
| Status | Recruiting |
| Started | September 30, 2019 |
| Main results expected | September 30, 2028 |
| Study ends | September 30, 2030 |
| Registry record updated | January 28, 2025 |
| Trial ID | NCT04262830 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are English and Spanish speaking individuals aged 13-39 who were diagnosed with cancer before age 22 and treated with anthracycline therapy at least two years prior.
✕Probably not a fit
Patients with contraindications to cardiac MRI or significant congenital heart disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on the cardiotoxic effects of anthracycline chemotherapy in pediatric cancer survivors. It aims to identify imaging markers of cardiac injury and dysfunction using cardiac MRI and other assessments. By examining a cohort of adolescents and young adults who were treated for cancer, the study seeks to develop improved diagnostic tests and treatment strategies to predict heart failure risk. The goal is to enhance early detection of cardiotoxicity before significant heart function changes occur.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic tools for early detection of heart issues in young cancer survivors, potentially preventing heart failure.
How similar studies have gone: Other studies have explored similar imaging techniques for assessing cardiotoxicity, indicating a growing interest in this area, though this specific approach may be novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * English and Spanish speaking male and female subjects, ages 13-39 years old * Diagnosis of cancer at age \<22 years * Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior. Exclusion Criteria: * Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants. * Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia. * Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus). * Pregnancy (at the time of enrollment).
Where it's running
-
Rady Children's Hospital
San Diego, California, United States Recruiting
Study contacts
- Principal investigator: Hari Narayan, MD — University of California San Diego, Rady Children's Hospital
- Study coordinator: Hari Narayan, MD
- Email: hnarayan@rchsd.org
- Phone: 8589665855 / 8589331718
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Machine-learning prediction of heart damage from anthracycline or HER2 cancer therapies
We will see if a machine-learning score can predict which adults starting anthracycline or HER2-targeted cancer therapies will develop heart damage within one year.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
AI-based assessment of heart function using ECG wearable monitors
This study tests if a new AI tool using a wearable heart monitor can accurately check heart function in people with heart failure compared to traditional heart scans.
-
Exercise and fitness program for breast cancer survivors to improve heart health
This study tests whether a special exercise and yoga program can help breast cancer survivors over 60 improve their heart health and physical fitness after treatment.
-
Stopping heart failure medications in cancer survivors with heart dysfunction
This study is testing if cancer survivors with improved heart function can safely stop taking their heart failure medications to see if it reduces their pill burden and side effects.
-
Long-term effects of breast cancer treatment on heart function
This study looks at how breast cancer treatments affect heart health in women who survived breast cancer to see if any heart problems they had in the past might get worse over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.